Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management

S. Monjazeb, Janice Wilson

Research output: Contribution to journalReview article

3 Scopus citations

Abstract

Epidermal growth factor receptor (EGFR) inhibitors are part of an emerging class of anticancer medicines known as "targeted therapy," which target pathways more specific to neoplastic proliferation than traditional chemotherapeutic agents. Adverse effects of such treatments are thought to be less severe, but can still be significant. Because EGFR is preferentially expressed in epithelial tissues, including the skin and hair follicle, cutaneous side effects of these agents are quite common. Not only can these toxicities severely affect patients' quality of life, but in some specific instances, they can be associated with increased response to therapy. It is of paramount importance that clinicians familiarize themselves with and understand the basic management of the range of cutaneous adverse effects caused by these drugs.

Original languageEnglish (US)
Pages (from-to)5-7
Number of pages3
JournalSkin therapy letter
Volume22
Issue number5
StatePublished - Sep 1 2017

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Epidermal Growth Factor Receptor Inhibitors: Cutaneous Side Effects and Their Management'. Together they form a unique fingerprint.

Cite this